Oil prices jumped more than 1% after reports that Israel was preparing an attack on Iran's nuclear facilities. Dollar and US ...

The US giant will pay the money upfront for distribution rights for SSGJ-707 outside of China; the deal could be worth up to ...

Pfizer shares climbed Tuesday after two punchy headlines hit the wire. FDA advisors are considering COVID-19 vaccines for ...

HONG KONG: China and Hong Kong stocks rose broadly on Tuesday, led by healthcare and consumer shares, as market sentiment ...

Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific antibody from 3Sbio Inc. that recently won ...

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

Pfizer Inc (NYSE:PFE) shares are moving higher Tuesday following multiple developments. Here's a look at what's going on.

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront ...

Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...